Article

2018-04-17 Economy

Goldman Sachs Analysts Question Whether Curing Patients Is Good for Business

h/t Instapundit
[Gizmodo] Recent advancements in science and medicine have put cures within reach for diseases that have long plagued humankind.

In a recent report, though, Goldman Sachs analysts posed an uncomfortable question that quickly sparked criticism.

"Is curing patients a sustainable business model?" analysts asked in an April 10 report entitled "The Genome Revolution," which CNBC first reported.

One-and-done cures enabled by gene editing, analyst Salveen Richter wrote in the note to clients this week, are near-miraculous innovations that stand to benefit patients immensely.

But they also present a challenge to business.

"While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow," she wrote.

Posted by g(r)omgoru 2018-04-17 10:43|| || Front Page|| [11132 views ] Top

#1 Rhetorical question of course.

Posted by Besoeker 2018-04-17 10:51|| 2018-04-17 10:51|| Front Page Top

#2 There will always be a need for genome fixing and cancer cures as there will always be issues.

So a one and done doesn't mean you develop and never use again. There will be another baby along the way that has issues.

Posted by DarthVader 2018-04-17 10:54|| 2018-04-17 10:54|| Front Page Top

#3 Except it shows you what's wrong with "Economics", Darth

Posted by g(r)omgoru 2018-04-17 11:15|| 2018-04-17 11:15|| Front Page Top

13:54 mossomo
13:51 mossomo
13:50 NoMoreBS
13:50 Abu Uluque
13:44 Abu Uluque
13:41 NoMoreBS
13:39 Abu Uluque
13:36 mossomo
13:36 swksvolFF
13:32 mossomo
13:26 Frank G
13:12 Regular joe
13:12 mossomo
13:11 swksvolFF
13:08 Abu Uluque
13:00 swksvolFF
12:59 Regular joe
12:55 Skidmark
12:53 Skidmark
12:52 Abu Uluque
12:50 Abu Uluque
12:49 Skidmark
12:48 NN2N1
12:46 Skidmark